ArticleInternational journal of clinical and experimental pathology2014
Prognostic value of Ki67 index in gastrointestinal stromal tumors.
Article in International journal of clinical and experimental pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Ki67 is a biological marker of malignant risk of gastrointestinal stromal tumors: A systematic review and meta-analysis.Medicine · 2017Pooled it
- Characterizing gastrointestinal stromal tumors and evaluating neoadjuvant imatinib by sequencing of endoscopic ultrasound-biopsies.World journal of gastroenterology · 2017Trial
- Giant jejunal gastrointestinal stromal tumor presenting as refractory anemia: a case report of complex R0 resection.International journal of surgery case reports · 2026Article
- A Case Report and Literature Review of a Rectal Gastrointestinal Stromal Tumor.ACG case reports journal · 2026Article
- Small bowel volvulus revealing advanced jejunal gastrointestinal stromal tumor with diffuse metastases: a case report.Annals of medicine and surgery (2012) · 2026Article
- Article
- Article
- Article
- Can CT Radiomics Predict the Ki-67 Index of Gastrointestinal Stromal Tumors (GISTs)? A Systematic Review and Meta-Analysis.Cancers · 2025Review
- Exploring nanotechnology solutions for improved outcomes in gastrointestinal stromal tumors.Heliyon · 2024Review
- Radiomics signatures based on contrast-enhanced CT for preoperative prediction of the Ki-67 proliferation state in gastrointestinal stromal tumors.Japanese journal of radiology · 2023Article
- Beneficial Proapoptotic Effect of Heterobasidion Annosum Extract in Colorectal Cancer Xenograft Mouse Model.Molecules (Basel, Switzerland) · 2023Article
- Gastrointestinal Stromal Tumors: Recurrence and Survival Analysis of 49 Patients.Middle East journal of digestive diseases · 2023Article
- The relationship between Ki-67 expression and imaging signs and pathological features in GISTs.Frontiers in surgery · 2023Article
- Building contrast-enhanced CT-based models for preoperatively predicting malignant potential and Ki67 expression of small intestine gastrointestinal stromal tumors (GISTs).Abdominal radiology (New York) · 2022Article
- GIST: Correlation of risk classifications and outcome.Journal of medicine and life · 2022Article
- Ki67 for evaluating the prognosis of gastrointestinal stromal tumors: A systematic review and meta-analysis.Oncology letters · 2022Article
- Clinicopathologic Characteristics and Prognosis of PDGFRA-Mutant Gastrointestinal Stromal Tumors: A Large-Scale, Multi-Institutional, Observational Study in China.Advances in therapy · 2022Observational
- Gastric and Small Intestine Gist: Results of 156 Cases in 20 Years.Journal of gastrointestinal cancer · 2022Article
- Value ofJournal of gastrointestinal oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKi67 index is one of the most important immunocytochemical markers of proliferation in tumors, but the criterion of Ki67 index in GISTs was not well-defined yet. Our study aims to fully evaluate the prognostic value of Ki67 index in GIST patients and efficiency of imatinib adjuvant therapy.
methodsClinicopathological data were confirmed by pathological diagnosis and clinical recorders. Recurrence-free survivals (RFS) were evaluated in 418 GIST patients (370 cases only taken the surgery and 48 high-risks taken imatinib adjuvant therapy after R0 resection).
resultsTwo cutoff levels of Ki67 index (>5 and >8%) were established in our study through statistical analysis. Ki67 index (≤5, 6-8 and >8%) is an independent prognostic factor for RFS of GIST patients. Ki67 index>8% can precisely sub-divide high-risk GISTs effectively with different outcomes, and high-risk patients with Ki67 index>8% showed a poorer prognosis even with imatinib adjuvant therapy.
conclusionKi67 index is an effective complementation of modified NIH criteria in predicting the prognosis of GISTs, and Ki67 index>8% may act as an unfavorable factor for imatinib adjuvant therapy.
Indexed as
Identifiers
24966939PMC4069950What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.